|
|
Post by ktim on Mar 18, 2020 11:48:05 GMT -5
Hopefully what we end up with from this PR isn't limited to a class action lawsuit like is now being directed at INO.
Some people got slaughtered by INO, though I'd blame the pump and dumpers more than INO itself.
|
|
|
|
Post by peppy on Mar 18, 2020 11:51:40 GMT -5
To me, this is a very wise decision. At this difficult time, this will help immensely to keep Mannkind's shares from being crushed by the market day to day.  |
|
|
|
Post by awesomo on Mar 18, 2020 11:56:19 GMT -5
Hopefully what we end up with from this PR isn't limited to a class action lawsuit like is now being directed at INO. Some people got slaughtered by INO, though I'd blame the pump and dumpers more than INO itself. I'll take a pump and dump to be honest. |
|
|
|
Post by ktim on Mar 18, 2020 12:13:19 GMT -5
Hopefully what we end up with from this PR isn't limited to a class action lawsuit like is now being directed at INO. Some people got slaughtered by INO, though I'd blame the pump and dumpers more than INO itself. I'll take a pump and dump to be honest. Unless part of the dump is an equity raise, I think the long term effects of pump and dump cycles is that the stock is perceived as highly volatile/risky. Probably not a good thing unless one is wishing to take advantage of the short term trading opportunity it presents. |
|
|
|
Post by mango on Mar 18, 2020 12:18:10 GMT -5
Inovio had the corrupt, Short and Distort player, Citron Research publish blatantly false, inaccurate and misleading claims/info about the company and it's technology and capabilities. Inovio is a great company with enormous potential. I believe the class action lawsuit will go nowhere, but an investigation into Citron Research is warranted.
|
|
|
|
Post by ktim on Mar 18, 2020 12:43:59 GMT -5
INO may be promising, but the pump induced run up wasn't justified and really hurt some naive investors. Perhaps they will be a player in vaccines for COVID-19 when they come out 12 to 18 months from now. There likely will be multiple companies with successful vaccines in that time period.
|
|
|
|
Post by sportsrancho on Mar 18, 2020 13:49:46 GMT -5
CEO of Merck said on CNBC it’ll be at least 18 months before there’s a cure.
|
|
|
|
Post by mango on Mar 18, 2020 14:13:08 GMT -5
INO may be promising, but the pump induced run up wasn't justified and really hurt some naive investors. Perhaps they will be a player in vaccines for COVID-19 when they come out 12 to 18 months from now. There likely will be multiple companies with successful vaccines in that time period. Are you saying Inovio is responsible for the "pump induced run up?" or implying MMs and manipulators are responsible? or is it something else you meant? Inovio didn't sensationalize anything or make any inaccurate claims. They were one of ten companies invited to the White House to speak to the President and VP. Inovio is the leader in coronavirus vaccine development, developed their COVID-19 vaccine in 3 hours, will begin human clinical trials in April, and expect to have their COVID-19 vaccine ready for emergency mass supply before the end of this year. Some people, and some companies, really take offense to that because their technology and know-how is not as advanced as Inovio's, and so their timelines are much longer and slower. |
|
|
|
Post by rfogel on Mar 18, 2020 14:17:32 GMT -5
|
|
|
|
Post by itellthefuture777 on Mar 18, 2020 14:17:50 GMT -5
If Mannkinds Technology is where I think it is the creation time is only 3 months to load a particle to producing. Cost of Goods streamlined..They also have the ability to make 3 million per year and modular expandable robotic factory double award winning at that~ Sterling equipment...Superior delivery system..nano technology to fight a nano coronavirus..from closing off your lungs in ARD..
Light the fires and give daily transparent press briefings on the progress Mannkind...should scare your competition...and ignite interest~~
|
|
|
|
Post by itellthefuture777 on Mar 18, 2020 14:19:22 GMT -5
Get Andrea Leone-Bay back at Mannkind for the effort Michael..as needed National Emergency at stake..so..
|
|
|
|
Post by itellthefuture777 on Mar 18, 2020 14:38:57 GMT -5
Immix Biopharma, Inc.,
Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
|
|
|
|
Post by itellthefuture777 on Mar 18, 2020 14:40:21 GMT -5
Immix Biopharma, Inc., Sherie Morrison, PhD
Scientific Advisory Board
•Distinguished Professor of Microbiology, Immunology and Molecular Genetics at UCLA
•Renowned expert in antibodies and antibody-related proteins
•First to express genetically engineered antibodies using gene transfection
More Brain Power~~
|
|
|
|
Post by itellthefuture777 on Mar 18, 2020 14:44:10 GMT -5
Immix Biopharma, Inc.,
Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
This guy looks like a heavyweight in Brain power~ |
|
|
|
Post by rfogel on Mar 18, 2020 14:54:05 GMT -5
Immix Biopharma, Inc.,
Vladimir Torchilin, PhD
Co-Founder
Dr. Torchilin is a Distinguished University Professor at Northeastern University, where he directs the Center for Pharmaceutical Biotechnology and Nanomedicine and has served as Chair of the Department of Pharmaceutical Sciences.
Prior to Northeastern, Prof. Torchilin was the Head of Chemistry at Harvard Medical School and Mass General Hospital. He holds more than 45 patents, published more than 400 papers, serves as the Editor-in-Chief of Drug Delivery and Current Drug Discovery Technologies, and was named the world’s 2nd most prolific researcher in pharmacology and toxicology by Times Higher Education.
The other co-founder runs a primary care clinic: www.rachmanmedical.com/It indicates he also specializes in "diabetes management." Maybe that was the connection to Mannkind. |
|
